Sol-Gel Technologies (SLGL) Common Equity (2016 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Common Equity of $51.4 million for Q1 2026, up 154.84% year-over-year from $20.2 million in Q1 2025, and up 125.36% quarter-over-quarter from $22.8 million in Q4 2025.
Sol-Gel Technologies (SLGL) Common Equity (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Common Equity for 11 consecutive years, with $51.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 154.84% year-over-year to $51.4 million; the TTM figure through Mar 2026 stood at $51.4 million (up 154.84% YoY), while the FY2025 annual figure was $22.8 million, down 20.93% from the prior year.
- Common Equity climbed to $51.4 million in Q1 2026 per SLGL's latest filing, from $22.8 million in the prior quarter.
- Across five years, Common Equity topped out at $233.6 million in Q2 2022 and bottomed at $20.2 million in Q1 2025.
- Historically, Common Equity has averaged $59.6 million across 5 years, with a median of $38.6 million in 2023.
- Annual changes were most pronounced in 2022 — Common Equity soared 495.17% — and 2023, when it sank 81.3%.
- Sol-Gel Technologies' Common Equity stood at $42.2 million in 2022, then decreased by 8.45% to $38.6 million in 2023, then decreased by 25.34% to $28.8 million in 2024, then slipped by 20.93% to $22.8 million in 2025, then surged by 125.36% to $51.4 million in 2026.
- Business Quant data shows SLGL's Common Equity at $51.4 million in Q1 2026, $22.8 million in Q4 2025, and $26.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | 51.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.41 Mn |
| Dec 31, 2025 | 22.81 Mn |
| Sep 30, 2025 | 26.03 Mn |
| Jun 30, 2025 | 31.88 Mn |
| Mar 31, 2025 | 20.17 Mn |
| Dec 31, 2024 | 28.85 Mn |
| Sep 30, 2024 | 34.71 Mn |
| Jun 30, 2024 | 34.90 Mn |
| Mar 31, 2024 | 32.65 Mn |
| Dec 31, 2023 | 38.64 Mn |
| Sep 30, 2023 | 43.13 Mn |
| Jun 30, 2023 | 48.30 Mn |
| Mar 31, 2023 | 43.60 Mn |
| Dec 31, 2022 | 42.21 Mn |
| Sep 30, 2022 | 47.47 Mn |
| Jun 30, 2022 | 233.59 Mn |
| Mar 31, 2022 | 233.22 Mn |
| Dec 31, 2021 | 55.59 Mn |
| Sep 30, 2021 | 41.44 Mn |
| Jun 30, 2021 | 39.25 Mn |